New drug DS3790a shows promise in early blood cancer trial
NCT ID NCT07220616
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study tests a new drug called DS3790a in people with blood cancers like leukemia or lymphoma. The main goals are to check safety and see if the drug can shrink tumors. About 420 adults will take part, and the drug is given alone or with other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGNew York, New York, 10065, United States
Contact
-
Research Site
RECRUITINGLille, 59037, France
Contact
-
Research Site
RECRUITINGNagoya, 464-8681, Japan
Contact
-
Research Site
RECRUITINGTokyo, 104-0045, Japan
Contact
-
Research Site
RECRUITINGTokyo, 135-8550, Japan
Contact
Conditions
Explore the condition pages connected to this study.